2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2807

Management Of Vertebral Osteomyelitis: A Randomized Clinical Trial Comparing 6 Versus 12 Weeks Of Antibiotic Treatment
Abstract Number: 861

Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey
Abstract Number: 1025

Mapping The Health Assessment Questionnaire On a Preference Based Utility Measure In a Large Canadian Rheumatoid Arthritis Cohort: Results From The Ontario Best Practices Research Initiative
Abstract Number: 1704

Mapping The Shared and Distinct HLA Alleles For Seropositive and Seronegative Rheumatoid Arthritis
Abstract Number: 269

Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program
Abstract Number: 2892

Masp-1/3 Deficient MRL/Lpr Mice Lack The Alternative Complement Pathway Activation and Are Protected From Development Of Lupus-Like Glomerulonephritis
Abstract Number: 1900

Mass Spectrometry-Based Salivary Proteomics For The Discovery Of Novel Diagnostic Biomarkers For Primary Sjögren’s Syndrome and Its Clinical Subsets
Abstract Number: 2500

Mast Cells Are a Major Source Of IL-17 In Synovium and Extra-Articular Tissues In Spondyloarthritis Related Diseases
Abstract Number: 2834

Maternal data Analysis Of The French Registry Of 205 Cases Of Immune Congenital Heart Block (neonatal lupus)
Abstract Number: 1274

Maternal Vitamin D, Fetal C-Reactive Protein and Brain Natriuretic Peptide Associate With The Development and Morbidity Of Cardiac Neonatal Lupus
Abstract Number: 1331

Mathematical Model To Predict The Early Responders In a Monocentric Cohort Of Patients With Rheumatoid Arthritis Treated By Anti TNF-Alpha
Abstract Number: 1677

May Giant Cell Arteritis Be Characterized By Different Clinical Entity and Long-Term Outcome?
Abstract Number: 1525

Measurement Of Lateral Spinal Flexion and Schober Is Sufficient To Be Informed About Spinal Mobility In Patients With Ankylosing Spondylitis: 12-Year OASIS Results
Abstract Number: 1003

Measuring Economic Value of Morning Stiffness; Consistency Over 1 Year
Abstract Number: 2122

Mechanical Back Pain Demonstrates Better Response To Celecoxib Than Acetaminophen Despite Lack Of MRI-Defined Inflammatory Changes In The Spine

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].